Petrelintide

An amylin analog as an alternative to GLP-1 receptor agonists for weight management

Petrelintide is an investigational long-acting amylin analog for once-weekly subcutaneous administration that has been designed with chemical and physical stability at neutral pH, minimizing fibrillation and allowing for co-formulation with other peptides. 

Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin analogs have been shown to increase satiety by a direct effect on the amylin receptor and by restoring sensitivity to the hormone leptin. This is in contrast to GLP-1 receptor agonists that primarily lower body weight by reducing appetite.

Current clinical or preclinical data suggest a potential for long-acting amylin analogs to deliver a reduction in body weight that is comparable to GLP-1 receptor agonists but with improved tolerability for a better patient experience and a high-quality weight loss through the preservation of lean muscle.

Zealand Pharma 1197
 
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
REGISTRATION
Obesity
PROGRAM Petrelintide
Phase 1

Development status

We are evaluating petrelintide in a Phase 1b multiple ascending dose (MAD) clinical trial.

In Part 1 of this Phase 1b MAD trial, low doses of 0.6 mg and 1.2 mg petrelintide administered weekly over six weeks showed an average weight loss of -5.3% and -5.1%, respectively. Petrelintide was well-tolerated with no serious or severe treatment-emergent adverse events and no withdrawals from the trial. All gastrointestinal adverse events reported were mild. These results were reported in 2023.

Part 2 of the MAD trial is currently exploring significantly higher doses of petrelintide over a longer duration of 16 weeks.

In a previous Phase 1 trial to assess single doses, one single dose of petrelintide 2.4 mg led to average weight loss of -4.2% after one week. These results were reported in 2023.

Petrelintide is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.

Related scientific publications

All scientific publications
  • Obesity Week

    Safety, Tolerability, and Clinical Effects of ZP8396, an Amylin Analog: Multiple Ascending Dose Trial

  • Obesity Week

    Potent Weight Loss Effects of Amylin Analog ZP8396 in Combination with Tirzepatide in DIO Rats

  • ADA Scientific Sessions

    Safety, Tolerability, and Clinical Effects of ZP8396, a Novel Long Acting Amylin Analog: A Single Ascending Dose Rrial

  • Obesity Week

    Amylin Analog ZP8396 Co-formulated With Semaglutide Provides Additive Anti-obesity Effect in DIO Rat

Learn about clinical trials involving petrelintide

Obesity

More about the disease area

Overweight and obesity are associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation.

  • Learn more
  • Crowd 1